PHIO (Phio Pharmaceuticals) FCF Yield %: -90.45 (As of Jul. 10, 2026)


PHIO Phio Pharmaceuticals Corp PHIO
28 GF Score
Price $1.02
! 1 Warning Sign
View Full Analysis

What is Phio Pharmaceuticals FCF Yield %?

Phio Pharmaceuticals PHIO -0.97% 28 FCF Yield % is -90.45 as of Jul. 10, 2026. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,408 Biotechnology companies, Phio Pharmaceuticals ranks worse than 89.84% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Phio Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-10.72 Mil, and Market Cap is $11.85 Mil. Therefore, Phio Pharmaceuticals's FCF Yield % for today is -90.45%.

The historical rank and industry rank for Phio Pharmaceuticals's FCF Yield % or its related term are showing as below:

PHIO' s FCF Yield % Range Over the Past 10 Years
Min: -189479.4   Med: -2254.87   Max: -69.55
Current: -90.45


During the past 13 years, the highest FCF Yield % of Phio Pharmaceuticals was -69.55%. The lowest was -189479.40%. And the median was -2254.87%.

PHIO's FCF Yield % is ranked worse than
89.84% of 1408 companies
in the Biotechnology industry
Industry Median: -9.41 vs PHIO: -90.45

Phio Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Phio Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Phio Pharmaceuticals FCF Yield % Related Terms


Phio Pharmaceuticals FCF Yield % Historical Data

* Premium members only.

The historical data trend for Phio Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phio Pharmaceuticals FCF Yield % Chart

Phio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -88.21 -240.09 -377.94 -228.16 -65.51

Phio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.24 -90.21 -58.33 -68.18 -112.98

PHIO vs PBM, KPRX, OSRH: FCF Yield % Comparison

For the Biotechnology subindustry, Phio Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's FCF Yield % falls into.


PHIO
28GF Score
Phio Pharmaceuticals Corp PHIO
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phio Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Phio Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-7.991 / 12.19785
=-65.51%

Phio Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-4.003 * 4 / 14.17274
=-112.98%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -90.45 mean?
Phio Pharmaceuticals (PHIO) has a FCF Yield % of -90.45 as of Jul. 10, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Phio Pharmaceuticals and its competitors. According to the industry distribution chart, Phio Pharmaceuticals ranks #1265 out of 1408 companies in the Biotechnology industry, placing it in the top 89.8%.
Is Phio Pharmaceuticals' FCF Yield % too high?
Phio Pharmaceuticals' current FCF Yield % is -90.45. Based on the distribution chart, Phio Pharmaceuticals ranks #1265 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' FCF Yield % compare to PBM and KPRX?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #1265 out of 1408 companies for FCF Yield %. This places Phio Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Phio Pharmaceuticals and its competitors. Phio Pharmaceuticals's current FCF Yield % is -90.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current FCF Yield % of -90.45. The current FCF Yield % is -90.45. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current FCF Yield % is -90.45 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Phio Pharmaceuticals Business Description

Address 411 Swedeland Road, Suite 23-1080, King of Prussia, PA, USA, 19406
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score

Get the complete analysis for PHIO

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price